GiraldoKatoMD

Oncology • Phoenix, AZ

Physician

Join to view full profile

Dr. Kato is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kato's full profile

Already have an account?

Office
2222 E Highland Ave #400
Phoenix, AZ 85016
Phone+1 602-277-4868

Education & Training

Wake Forest University Baptist Medical CenterFellowship, Hematology and Medical Oncology, 1997 - 1999
ECU Health Medical Center/East Carolina UniversityResidency, Internal Medicine, 1993 - 1996
Universidad Central del Este Facultad de MedicinaClass of 1985

Certifications & Licensure

AZ State Medical License 2000 - 2025
NC State Medical License 1996 - 2003
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2007 Aug 01
Terminated
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC) Start of enrollment: 2012 Feb 27
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

3 citations
Safety and efficacy of intravenous immunoglobulin (Flebogamma ® 10% DIF) in patients with immune thrombocytopenic purpura.
Shashikant Apte, Jordi Navarro-Puerto, Sharat Damodar, Vijay Ramanan, Joseph M John
Immunotherapy. 2019-02-01
155 citations
Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer
Anne F. Schott, Lori J. Goldstein, Massimo Cristofanilli, Pier Adelchi Ruffini, Susan McCanna
Clinical Cancer Research. 2017-09-15

Professional Memberships

American Society of Clinical Oncology - ASCO
Member